The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.
 
Gita Thanarajasingam
No Relationships to Disclose
 
Amylou C. Dueck
Consulting or Advisory Role - Bayer; Phytogine
Travel, Accommodations, Expenses - Pfizer
 
Paul J Novotny
No Relationships to Disclose
 
Thomas Matthew Habermann
No Relationships to Disclose
 
Ranjana H. Advani
Consulting or Advisory Role - AstraZeneca; Autolus; Bayer; Bristol-Myers Squibb; Cell Medica; Genentech/Roche; Gilead Sciences; Pharmacyclics; Seagen; Takeda
Research Funding - Agensys (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Randy D. Gascoyne
Consulting or Advisory Role - Roche/Genentech
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Andrew Quon
No Relationships to Disclose
 
Erik Ranheim
No Relationships to Disclose
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Celgene; Genentech; Juno Therapeutics; Pharmacyclics; Pharmacyclics; Roche
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen
 
Andrew M. Evens
Honoraria - Abbvie; Acerta Pharma; Affimed Therapeutics; Bayer; Celgene; Janssen Biotech; Kite/Gilead; Merck; Novartis; Pharmacyclics; Research to Practice; Seagen; Spectrum Pharmaceuticals; Verastem
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma; Affimed Therapeutics; Bayer; Celgene; Janssen Oncology; Kite, a Gilead company; Kite/Gilead; Merck; Novartis; Seagen; Spectrum Pharmaceuticals
Research Funding - Merck; Seagen; Tesaro
Travel, Accommodations, Expenses - Abbvie/Genentech; Affimed Therapeutics; Bayer; Celgene; Janssen Biotech; Merck; Novartis; Pharmacyclics; Research to Practice; Seagen; Spectrum Pharmaceuticals; Verastem
 
Fangxin Hong
No Relationships to Disclose